During the first few weeks when fatigue may be higher, listen to your body and avoid pushing too hard
Questions to Discuss With Your Provider When considering compounded generic medical weight loss medications, ask about: How the formulation is tailored to your medical history
6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B) Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs
(2) Dose adjustment: Start elderly patients on a low dose and gradually adjust according to their tolerance and response, avoiding high doses
Zepbound now carries an obstructive sleep apnea indication as well as its weight indications, and Foundayo (orforglipron), approved April 1 2026, is an oral product indicated for chronic weight management
Kosowska, A